Influence of EPHX1 c.337 T>C and UGT2B7*2 genetic polymorphisms on the requirement of carbamazepine maintenance dose in persons with epilepsy (PWE) of Southern part of India: a cross-sectional genetic association study
Objectives Carbamazepine (CBZ) is a first-line antiseizure drug used for focal onset seizures. It exhibits inter-individual variability in plasma carbamazepine levels and there are both genetic and non-genetic factors having a role in the requirement of CBZ maintenance dose. The aim was to study the influence of EPHX1 c.337 T>C and UGT2B7*2 genetic polymorphisms on CBZ maintenance dose requirement in persons with epilepsy. Methods Persons with epilepsy (PWE) of both gender of age 15–65 years on carbamazepine monotherapy who had been taking same maintenance dose for one year were eligible. Five milliliter of venous blood was collected in 10% EDTA under aseptic precautions. After centrifugation, the cellular component was used for DNA extraction and genotyping. For three genotypes of EPHX1 c.337 T>C and UGT2B7*2, the differences in mean carbamazepine dose were analyzed using Analysis of Variance (ANOVA). An unpaired t-test was used to draw a comparison between the genotypes and CBZ maintenance dose requirement for dominant and recessive models of EPHX1 c.337 T>C and UGT2B7*2. A value of p<0.05 was considered to be statistically significant. Results For UGT2B7*2 (rs 7439366), CT required a higher dose (CT 626 mg/day and TT 523 mg/day) but not found to be significant (p-value 0.167). PWE carrying CT genotype of EPHX1 c.337 T>C had 62 mg higher dose when compared to homozygous mutant CC (590 mg/day for CT and 528 mg/day for CC) but p-value was not found to be significant (p-value 0.835). Conclusions The results of our study done in 115 PWE showed there was a lack of association between SNPs of EPHX1 c.337 T>C, UGT2B7*2 and CBZ maintenance dose requirement in Southern part of India and this finding has to be confirmed in a larger sample size..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Drug metabolism and personalized therapy - 38(2023), 2 vom: 01. März, Seite 191-197 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Venkatraman, Shravan [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2023 Walter de Gruyter GmbH, Berlin/Boston |
|---|
| doi: |
10.1515/dmpt-2022-0157 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
GRUY00897392X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | GRUY00897392X | ||
| 003 | DE-627 | ||
| 005 | 20231205155358.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230813s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/dmpt-2022-0157 |2 doi | |
| 035 | |a (DE-627)GRUY00897392X | ||
| 035 | |a (DE-B1597)dmpt-2022-0157-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Venkatraman, Shravan |e verfasserin |0 (orcid)0000-0002-4376-7960 |4 aut | |
| 245 | 1 | 0 | |a Influence of EPHX1 c.337 T>C and UGT2B7*2 genetic polymorphisms on the requirement of carbamazepine maintenance dose in persons with epilepsy (PWE) of Southern part of India: a cross-sectional genetic association study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2023 Walter de Gruyter GmbH, Berlin/Boston | ||
| 520 | |a Objectives Carbamazepine (CBZ) is a first-line antiseizure drug used for focal onset seizures. It exhibits inter-individual variability in plasma carbamazepine levels and there are both genetic and non-genetic factors having a role in the requirement of CBZ maintenance dose. The aim was to study the influence of EPHX1 c.337 T>C and UGT2B7*2 genetic polymorphisms on CBZ maintenance dose requirement in persons with epilepsy. Methods Persons with epilepsy (PWE) of both gender of age 15–65 years on carbamazepine monotherapy who had been taking same maintenance dose for one year were eligible. Five milliliter of venous blood was collected in 10% EDTA under aseptic precautions. After centrifugation, the cellular component was used for DNA extraction and genotyping. For three genotypes of EPHX1 c.337 T>C and UGT2B7*2, the differences in mean carbamazepine dose were analyzed using Analysis of Variance (ANOVA). An unpaired t-test was used to draw a comparison between the genotypes and CBZ maintenance dose requirement for dominant and recessive models of EPHX1 c.337 T>C and UGT2B7*2. A value of p<0.05 was considered to be statistically significant. Results For UGT2B7*2 (rs 7439366), CT required a higher dose (CT 626 mg/day and TT 523 mg/day) but not found to be significant (p-value 0.167). PWE carrying CT genotype of EPHX1 c.337 T>C had 62 mg higher dose when compared to homozygous mutant CC (590 mg/day for CT and 528 mg/day for CC) but p-value was not found to be significant (p-value 0.835). Conclusions The results of our study done in 115 PWE showed there was a lack of association between SNPs of EPHX1 c.337 T>C, UGT2B7*2 and CBZ maintenance dose requirement in Southern part of India and this finding has to be confirmed in a larger sample size. | ||
| 700 | 1 | |a Ramasamy, Kesavan |4 aut | |
| 700 | 1 | |a Nair, Pradeep P. |4 aut | |
| 700 | 1 | |a Rajendran, Priyadharsini |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug metabolism and personalized therapy |d De Gruyter, 2015 |g 38(2023), 2 vom: 01. März, Seite 191-197 |h Online-Ressource |w (DE-627)GRUY00052929X |w (DE-600)2822040-7 |w (DE-576)433099526 |x 2363-8915 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2023 |g number:2 |g day:01 |g month:03 |g pages:191-197 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1515/dmpt-2022-0157 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_GRUY | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | b | k | |a 44.40 |j Pharmazie |j Pharmazeutika |q VZ |
| 951 | |a AR | ||
| 952 | |d 38 |j 2023 |e 2 |b 01 |c 03 |h 191-197 | ||